&nbsp;

CCO_SilentEnemyDigital_Ojibway.pdf

Sep 2022

Document

CCO_SilentEnemyDigital-OjiCree.pdf

Sep 2022

Regimen

CISPGEMC(W)+DURV

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Funding:

New Drug Funding Program

Durvalumab - Locally Advanced Unresectable or Metastatic Biliary Tract Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Apr 2024

Regimen

CISPPEME+NIVL

Cancer Type:

Lung,

Non-Small Cell

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Nivolumab - Neoadjuvant Treatment for Non-Small Cell Lung Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

May 2024

Regimen

CISPVINO+NIVL

Cancer Type:

Lung,

Non-Small Cell

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Nivolumab - Neoadjuvant Treatment for Non-Small Cell Lung Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

May 2024

Regimen

CISPGEMC+NIVL

Cancer Type:

Lung,

Non-Small Cell

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Nivolumab - Neoadjuvant Treatment for Non-Small Cell Lung Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

May 2024

Document

CAR T-cell therapy for adult relapsedrefractory lymphoma (third or subsequent line).pdf

Oct 2022

Regimen

NIVL(MNT)

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab - First-line Treatment of Advanced Gastric, Esophageal, and Esophagogastric Junction Adenocarcinoma

Drugs Used:

nivolumab

... Show more tags

Quick Link(s):

Regimen Monograph

Aug 2024

Document

CancerDrugFundingFirstNationsInuitMétisUrbanIndigenousPeople.pdf

Nov 2022

Document

CoP_Fall2022.pdf

Nov 2022

Document